Halozyme Therapeutics price to free cash flow HALO

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026: 17.7×
9-year median: 18.1×
Against its 9-year history: 47th; percentile: 0 is its lowest day, 100 its highest
9-year range: 11.3× to 129×
Peer median: 27.7×

Halozyme Therapeutics' price to free cash flow is 17.7× as of Oct 23, 2026.

That is below its 9-year median of 18.1×, close to the middle of its last 9 years.

Over that time it ranged from 11.3× in Mar 2026 to 129× in Apr 2021.

The median for 10 biotech stocks of a similar size is 27.7×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.7×	11.3×	17.7×
2025	13.4×	12.1×	18.9×
2024	15.6×	12.6×	19.8×
2023	13.8×	13.8×	31.6×
2022	32.4×	16.0×	33.8×
2021	21.4×	17.2×	129×
2020	n/m a value too high to mean anything
2019	27.1×	23.4×	27.1×
2018	22.7×	17.4×	26.3×

Against its peers

Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.

Company	Price to free cash flow
HALOHalozyme Therapeutics	17.7×
NBIXNeurocrine Biosciences	16.7×
EXELExelixis	13.6×
TECHBIO-TECHNE	43.2×
RGENRepligen	89.2×
KRYSKrystal Biotech	35.8×
INCYIncyte	12.2×
UTHRUnited Therapeutics	23.1×
ALNYAlnylam Pharmaceuticals	37.8×
ONCBeOne Medicines	32.3×
REGNRegeneron Pharmaceuticals	22.0×
Peer median	27.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Halozyme Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.